Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
13.50
-1.06 (-7.28%)
Jul 13, 2026, 4:00 PM EDT - Market closed
Korro Bio Employees
Korro Bio had 49 employees as of March 31, 2026. The number of employees decreased by 63 or -56.25% compared to the same quarter last year.
Employees
49
Change
-63
Growth
-56.25%
Revenue / Employee
$78,408
Profits / Employee
-$2,316,286
Market Cap
194.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 49 | -63 | -56.25% | 49 | 0 |
| Dec 31, 2025 | 58 | -46 | -44.23% | 58 | 0 |
| Sep 30, 2025 | 87 | -8 | -8.42% | 87 | 0 |
| Jun 30, 2025 | 92 | 0 | - | 92 | 0 |
| Mar 31, 2025 | 112 | 18 | 19.15% | 112 | 0 |
| Dec 31, 2024 | 104 | 2 | 1.96% | 104 | 0 |
| Sep 30, 2024 | 95 | -1 | -1.04% | 95 | 0 |
| Jun 30, 2024 | 92 | 4 | 4.55% | 92 | 0 |
| Mar 31, 2024 | 94 | 6 | 6.82% | 94 | 0 |
| Dec 31, 2023 | 102 | - | - | 101 | 1 |
| Sep 30, 2023 | 96 | - | - | 95 | 1 |
| Jun 30, 2023 | 88 | - | - | 88 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Codexis | 146 |
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Nkarta | 108 |
| Immunic | 95 |
| NovaBridge Biosciences | 30 |
| Whitehawk Therapeutics | 29 |
KRRO News
- 3 days ago - Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Korro Bio initiated with an Outperform at LifeSci Capital - TheFly
- 6 weeks ago - Korro to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Korro Bio selects KRRO-111 as development candidate - TheFly
- 2 months ago - Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 2 months ago - Korro Bio price target lowered to $15 from $20 at H.C. Wainwright - TheFly
- 2 months ago - Korro Bio initiated with a Buy at Citi - TheFly
- 2 months ago - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire